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ABSTRACT  
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are 
infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) 
patients. Recent studies indicate pre-existing mutations (PEMs) can be detected in a higher 
percentage of CML patients using CD34+ stem/progenitor cells, and these mutations may 
correlate with imatinib resistance. We investigated KD mutations in CD34+ stem cells from 100 
CP-CML patients by multiplex ASO-PCR and sequencing ASO-PCR products at the time of 
diagnosis. PEMs were detected in 32/100 patients and included F311L, M351T, and T315I. After 
a median follow-up of 30 months (range 8–48), all patients with PEMs exhibited imatinib 
resistance. Of 68 patients without PEMs, 24 developed imatinib resistance. Mutations were 
detected in 21 of these patients by ASO-PCR and KD sequencing. All 32 patients with PEMs 
had the same mutations. In imatinib-resistant patients without PEMs, we detected F311L, 
M351T, Y253F, and T315I mutations. All imatinib-resistant patients without T315I and Y253F 
mutations responded to imatinib dose escalation. In conclusion, BCR-ABL PEMs can be 
detected in a substantial number of CP-CML patients when investigated using CD34+ 
stem/progenitor cells. These mutations are associated with imatinib resistance, and mutation 
testing using CD34+ cells may facilitate improved, patient-tailored treatment.  
 
 
Keywords: BCR-ABL, Chronic myeloid leukemia, chronic phase, kinase domain mutations, 
imatinib, CD34+  cells, pre-existing mutations. 
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INTRODUCTION 
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the 
t(9;22) chromosomal translocation. This translocation results in the formation of BCR-ABL 
fusion gene, which is central to the pathogenesis of CML. The BCR-ABL gene exhibits 
constitutive tyrosine kinase activity, resulting in myeloid proliferation 1. Imatinib mesylate, a 
tyrosine kinase inhibitor (TKI), induces durable responses in the majority of CML patients and is 
currently the standard of care for CML 2, 3. However, imatinib resistance, usually due to BCR-
ABL kinase domain (KD) point mutations, remains a significant problem in the management of 
CML patients 4-6. BCR-ABL mutations have varying effects on the patient’s sensitivity to 
imatinib and other TKIs, and may cause partial or complete resistance depending upon the nature 
and location of the mutation 5, 7-10. The presence of KD mutations has been studied mostly in the 
advanced phase of CML (accelerated phase and blast crisis), in chronic phase (CP) patients who 
develop resistance to imatinib, and in Philadelphia-positive (Ph+) acute lymphoblastic leukemia 5, 
10-13.  
 
BCR-ABL KD mutations can exist in newly diagnosed CP-CML patients and may affect the 
outcome of imatinib treatment 14-18. There are limited data available from imatinib-naive patients 
in CP-CML regarding the incidence of KD mutations, and the correlation of these mutations with 
the therapeutic response in unselected patients has not been established 14, 17-18. Although KD 
mutations are infrequently detected in newly diagnosed CP-CML patients 18, KD mutations were 
found in a substantial number of patients  when CD34+ stem cell  were analyzed 19-20. Recent 
studies indicated that a small population of CD34+ CML (stem/progenitor) cells are less 
responsive to imatinib and other TKIs, and act as a reservoir for the emergence of imatinib-
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resistant subclones 19, 21-23. Thus, the detection of pre-existing mutations (PEMs) in primitive 
stem/progenitor (CD34+) cells may have therapeutic and prognostic implications and is likely to 
be helpful in optimizing the management of CML patients 19-23. Large-scale studies to assess the 
role of BCR-ABL PEMs in CD34+ cells and their correlation with imatinib therapy in CP-CML 
are lacking. To address this issue, we analyzed 100 newly diagnosed CP-CML patients for BCR-
ABL PEMs  in CD34+ CML cells using allele-specific oligonucleotide polymerase chain reaction 
(ASO-PCR) and sequencing, and studied the outcome of these patients after imatinib treatment. 
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MATERIALS AND METHODS 
Patients and definitions 
One hundred newly diagnosed CP-CML patients were included in the study. All patients gave 
informed consent, and the study was approved by the institutional ethics committees of the four 
participating centers. All patients had newly diagnosed CP-CML at the time samples were taken, 
and patients with accelerated-phase or blast-crisis CML were excluded. Patients’ clinical 
characteristics are given in Table 1. 
CP was defined by the presence of less than 15% blasts, less than 20% basophils, and less than 
30% blasts and promyelocytes in the peripheral blood and bone marrow (BM) and no 
extramedullary blastic disease 24-26. Complete hematologic response (CHR), complete 
cytogenetic response (CCR), and a partial cytogenetic response were defined according to 
previously published response criteria 24-26. Briefly, CHR required the normalization of blood 
counts: leucocytes counts <10,000/mm3; normal differential counts without blasts, 
promyelocytes, or myelocytes; platelet counts from 150,000/mm3 to 450,000/mm3; and no 
evidence of extramedullary disease. CCyR was defined as 0% Ph+ cells in metaphase BM 
samples, and a partial cytogenetic response (PCyR) was defined as presence of 0–35% Ph+ cells 
in BM. Other categories included minor cytogenetic response (36–65% Ph+ cells in BM) and 
minimal cytogenetic response (66–95% Ph+ cells in BM). Complete molecular response (CMR) 
was defined as BCR-ABL fusion transcript negativity according to nested reverse transcriptase-
PCR. We could not record the major molecular response due to the non-availability of real-time 
quantitative PCR.   
Resistance patterns were adopted as defined by the LeukemiaNet guidelines 25. Primary or 
intrinsic resistance was defined by the failure to achieve CHR by 3 months, any cytogenetic 
response by 6 months, partial cytogenetic response by 12 months, and complete cytogenetic 
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response by 18 months. Acquired or secondary resistance was defined as the loss of previous 
hematological, cytogenetic, or molecular responses, sustained CHR that was followed by 
transformation to the accelerated or blastic phase, Ph+ clonal evolution, or the emergence of 
clinically relevant BCR-ABL KD mutations predicted to confer resistance 27. 
Isolation of CD34+ CML stem/progenitor cells 
BM mononuclear cells were isolated by Ficoll-Hypaque (Sigma Diagnostics, St Louis, MO) 
density gradient separation (specific gravity, 1.077) for 30 min at 400 × g. The cells were then 
suspended in a solution of 10% dimethylsulfoxide in fetal calf serum (FCS) and cryopreserved in 
liquid nitrogen until required 28. Before use, cells were thawed and stained with antibodies to 
CD34 directly conjugated to fluorescein isothiocyanate (Becton Dickinson Immunocytometry 
System, San Jose, CA). After staining for 30 min at 4°C, the cells were washed twice in 
phosphate-buffered saline containing 2% FCS (Stem Cell Technologies Inc.) and resuspended in 
2 μg/mL propidium iodide (Sigma). CD34+ cells were collected by fluorescence-activated cell 
sorting (FACS) using a FACSVantage cell sorter (Becton Dickinson, San Jose, CA) 29.  
Detection of pre-existing BCR-ABL mutations 
RNA and DNA were extracted from FACS-sorted CD34+ cells using TriZol and DNAzol 
(Invitrogen Life Technologies, Carlsbad, CA) methods, respectively 30. RNA and DNA quality 
was checked by spectrophotometry, gel electrophoresis, and by the amplification of the ABL 
gene 14, 30. As BCR-ABL PEMs are rare among wild-type BCR-ABL and thus cannot be detected 
by sequencing the whole BCR-ABL KD, we employed a very sensitive ASO-PCR assay for this 
purpose which has already been optimized and clinically validated using appropriate positive and 
negative controls elsewhere31. This assay can detect 18 of the most clinically relevant and 
common BCR-ABL mutations 14, 31-32. PCR amplifications were performed exactly as reported, 
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without changing any of the reagents, PCR mix formulations  and thermal profile31. A 30-μL 
mixture PCR mix was prepared as: 2 μL of DNA (corresponding to 100 ng of DNA); 1× 
TaqGold reaction buffer (Applied Biosystems, Foster City, CA); 1.5 mM MgCl2; 250 mM each 
of dATP, dCTP, dGTP, and dTTP (Pharmacia, Uppsala, Sweden); 0.5 U of AmpliTaq Gold 
polymerase (Applied Biosystems); and 50 pmol of forward and reverse ASO primer for each 
mutation. Thermocycling conditions consisted of 5 min at 94°C, 30 cycles of denaturation at 
94°C for 25 s, annealing at the indicated temperature for 25 s, and extension at 72°C for 30 s, 
and a final extension for 5 min at 72°C. The sequences of ASO primers specific for each 
mutation with the corresponding annealing temperatures are given in Table 2. HL60 cell line was 
used as negative control in ASO-PCR reactions.  Although we use pre-validated ASO-PCR 
assays as reproduced those assays using exactly same reaction conditions, reagents and PCR mix 
formulation, to eliminate the possibility of false-positive results, ASO-PCR products were 
sequenced using an automated ABI377 sequencer (Applied Biosystems). Sequences were 
analyzed with Sequence Analysis software V3.3 and Sequence Navigator software V1.0.1 
(Applied Biosystems). A mutation was considered present only if it was detected in both strands 
in two or more independent ASO-PCR amplified products 14, 31, 33.  
Imatinib treatment and response monitoring 
All patients were treated with 400 mg of imatinib/day. Clinical studies were performed in 
collaboration with CML treatment centers. Patients were monitored every 2 weeks for 
hematological response and every 3 months for cytogenetic and molecular response during 
imatinib treatment and follow-up. Secondary resistance, as described previously, was also 
monitored. For imatinib-resistant patients, second-generation TKIs were not available due to 
financial constraints. However, imatinib-resistant patients were treated with 600–800 mg of 
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imatinib/day, irrespective of presence or absence of PEMs 7. Patients were monitored regularly 
every 2 weeks for hematological response and every 12 weeks for cytogenetic and molecular 
responses after imatinib dose escalation.  
Detection of mutations after the manifestation of imatinib resistance 
All imatinib-resistant patients, irrespective of their PEM status, were investigated for BCR-ABL 
mutations using ASO-PCR 14, 31-32 as well as by DNA sequencing of the RT-PCR–amplified 
whole BCR-ABL KD. For RT-PCR and DNA sequencing of the BCR-ABL KD, we adopted the 
protocol described by Branford and Hughes 33 using an automated ABI377 sequencer (Applied 
Biosystems). HL60 cell line was used as a negative control in PCR and sequencing while KCL22 
cell line was used as a positive control. Sequences were analyzed with Sequence Analysis 
software V3.3 and Sequence Navigator software V1.0.1. To confirm mutation detection by 
sequencing, the opposite strand of the PCR product was sequenced. Moreover, the whole 
procedure of RNA extraction, RT-PCR, and sequencing was repeated once. Detection of the 
mutation was confirmed only if the same mutation was detected in both DNA strands as well as 
in the repeat analysis 15, 31, 33.  
Statistical Analysis 
Various clinical parameters, frequencies of imatinib resistance, and clinical response rates were 
compared in the two subgroups of patients with and without PEMs by Chi-square test using 
“Statistical Package for Social Sciences (SPSS)” software, version 17. A p-value of <0.05 was 
considered significant.  
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RESULTS 
Pre-existing and post-resistance BCR-ABL mutations 
BCR-ABL PEMs were detected in 32 out of 100 (32%) patients (Figure 2 and Table 3). We 
found three mutations, namely T315I, F311L, and M351T, either alone or in combination, as 
PEMs in this group of CML patients. The frequencies of the M351T, F311L, and T315I 
mutations were 87.5%, 50%, and 37.5%, respectively, either alone or in combination. Thus, 
M351T was the most common PEM, whereas T315I was the least common PEM detected 
(Figure 2). After 12–18 months of imatinib treatment (400 mg/day), all patients with BCR-ABL 
PEMs exhibited imatinib resistance (32/32, 100%). Upon re-investigation of BCR-ABL 
mutations in these patients using ASO-PCR and DNA sequencing, all patients had the same 
PEMs (Figure 1-3). Regarding the 68 patients without PEMs, imatinib resistance developed in 24 
(24/68, 35.3%) patients. BCR-ABL mutations (alone or in combination) were found in 21 of 
these patients (Table 3; Figure 2). By DNA sequencing, we were able to detect Y253F mutation 
in one of the patients as an acquired mutation (not as a PEM). T315I (12/21, 57.1%) and F311L 
(15/21, 71.5%) were the most common mutations in this group of patients, whereas M351T was 
detected in 11/21 (52.4%) patients.  
 
Association of mutations with clinical parameters 
No significant association was found between BCR-ABL KD PEMs and clinical parameters such 
as age, gender, type of BCR-ABL splice variant, white blood cell count, hemoglobin level, and 
platelet count. Imatinib-resistant CML patients with and without PEMs significantly differed 
with respect to time-to-detection-of-mutations (0 vs. 22.4±4.1 months, p=0.001), frequency of 
imatinib resistance (100% vs. 35.3%, p=0.01), CHR (71.9% vs. 91.2%, p=0.05), partial 
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hematological response (28.1% vs. 4.4%, p=0.01), minor cytogenetic response (15.6% vs. 8.8%, 
p=0.05), and CMR (0% vs. 41.2%, p=0.001), while no significant difference was found in terms 
of CCyR (53.1% vs. 55.9%) in the two groups,  
 
Management of resistant patients 
Resistant patients were treated with 600–800 mg of imatinib/day irrespective of PEM status. 
Patients harboring the T315I mutation (alone or in combination with F311L/M351T) did not 
exhibit any response, and progressed to accelerated-phase or blast-crises (12/32, 37.5%). In this 
group of patients with F311L/M351T PEMs (20/32, 62.5%), 16 patients (16/20, 80%) exhibited 
complete hematological, cytogenetic, and molecular responses to dose escalation, whereas four 
patients had partial cytogenetic responses (4/20, 20%). Fifteen CML patients without PEMs 
harboring a T315I mutation (alone or in combination with F311L/M351T/Y253F) did not 
respond to imatinib dose escalation and progressed to an advanced phase, whereas 7 out of 9 
(77.8%) patients harboring F311L/M351T mutations responded to dose escalation with complete 
hematological, cytogenetic, and molecular responses.  
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DISCUSSION 
CP-CML comprises of two types of cells. The majority of cells of the leukemic clone comprise a 
more mature type that is sensitive to TKIs. A small population of stem/progenitor (CD34+) cells 
is less sensitive to TKIs and is usually responsible for the development of resistance to therapy 
21-22. The BCR-ABL fusion gene is highly unstable in these primitive CML cells, and it is 
associated with frequent genetic alterations and mutations in BCR-ABL itself as well as in other 
genes such as p53 even in the absence of imatinib exposure 34. These naturally occurring genetic 
variants of BCR-ABL are known as pre-existing BCR-ABL mutations (PEMs) 14. Although the 
mechanism of clinical resistance to imatinib in CML varies widely, BCR-ABL KD point 
mutations are the leading cause of imatinib resistance 1, 11. If these mutations are present in 
critical regions in BCR-ABL, they can affect the binding of BCR-ABL protein with TKIs. The 
impaired binding of imatinib to these BCR-ABL mutants results in an inadequate response or 
loss of response. The mutant strains proliferate under selective pressure of TKIs after treatment 
initiation, leading to drug resistance 4, 11. These mutations are likely to be present at an early 
stage of disease evolution and become clinically manifested due to selective overgrowth after 
imatinib treatment 20, 23. 
 
Our study demonstrated that BCR-ABL PEMs might be found in a substantial number of newly 
diagnosed CP-CML patients if sensitive techniques such as ASO-PCR are used to assess CD34+ 
stem/progenitor cells, and these PEMs can significantly affect the outcome of imatinib therapy. 
BCR-ABL PEMs have been reported previously in newly diagnosed CP-CML patients in some 
studies 14-15, 17, 20, whereas others failed to detect any mutations in CP-CML patients before 
treatment initiation despite using sensitive techniques 18. Most of these studies were limited by a 
small sample size and CD34+ cell population was not specifically targeted for mutation 
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detection. Ours is the largest study to date on the incidence of naturally occurring BCR-ABL KD 
mutations using CD34+ cells and their association with imatinib resistance. Although more than 
50 BCR-ABL mutations have been reported, we analyzed for the 18 most common mutations as 
1) they cover more than 90% of the mutations responsible for imatinib resistance and not all the 
mutations are clinically relevant 18,20, 2) these 18 mutations can be detected by ASO-PCR which 
is the most sensitive technique to detect low copy number mutations like pre-existing BCR-ABL 
mutations, 3) we did not have facilities like denaturing HPLC to detect each and every mutation. 
Furthermore, detection of PEMs using ASO-PCR in a group of CML patients and detection of 
the same mutations after a period of time in that group using ASO-PCR as well as sequencing, is 
an indirect proof of validity of ASO-PCR for PEM detection with a minimal possibility of false 
positive results. The reasons for the presence of PEMs in almost one-third of our CP-CML 
patients are not entirely clear. We selected CD34+ cells to detect KD mutations because this 
compartment of primitive cells is likely to be the source of many of these mutations 14, and this, 
in combination with the use of a sensitive technique such as ASO-PCR in a larger number of 
patients, may explain our findings 19. Furthermore, it is also known that patients with advanced 
CP-CML are more likely to exhibit various KD mutations and primary resistance 5. Many 
patients in our area present late due to a lack of education, poor knowledge, and the use of 
traditional remedies before seeking medical advice. Therefore, we cannot rule out the possibility 
that our patient population may be skewed toward a higher-risk group of CP-CML patients 19. 
This could explain the higher mutation detection rate in some of these patients. It is tempting to 
speculate that this patient population may have a different disease biology, but we have no 
convincing evidence to support this notion 26.  
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Our findings are also supported by the work performed by Chu et al, who reported that KD 
mutations, when studied in CD34+ cells, were present even during complete cytogenetic 
remission in 5 of 13 CML patients treated with imatinib19. Recently, Jiang et al showed for the 
first time that these mutations were present even in very primitive (CD34−CD38−) stem cells 20. 
These findings support the idea that primitive CML cells have an intrinsic tendency to 
continuously acquire new mutations independent of therapy. Some of the mutations would be 
expected to confer imatinib resistance; others could lead to disease progression. It is the nature 
and timing of these mutations at diagnosis and during imatinib treatment that may explain the 
variable clinical responses in different patients 6, 15-16, 20, 34-35. Thus, the CML patients labeled 
clinically as imatinib responders and non-responders display significant differences in the 
frequencies of mutant BCR-ABL transcripts present in their pretreatment CD34+ cells 20, 34. 
 
Different BCR-ABL mutations have prognostic significance and vary in their effects on the 
sensitivity to standard doses and dose escalations of imatinib and as well as to other TKIs 3, 6-7, 13, 
36-39. All of our resistant patients were treated with imatinib dose escalation to 600–800 mg daily 
irrespective of their PEM status. We did not have an opportunity to treat imatinib-resistant 
patients with second-line TKIs because these agents were not obtainable due to the high cost and 
lack of funding (only imatinib is supplied free of cost to these patients by a non-governmental 
organization). Twelve patients with T315I PEM (alone or in combination with F311L and/or 
M351T) did not respond to imatinib dose escalation, and they progressed to accelerated-phase or 
blast-crisis. In this group of the patients with F311L and/or M351T mutations, 16 of 20 patients 
exhibited complete hematological, cytogenetic, and molecular responses to dose escalation, 
whereas the other four patients exhibited partial cytogenetic responses. Fifteen CML patients 
without PEMs harboring T315I mutation (alone or in combination with F311L, M351T, and/or 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
64
5.
1 
: P
os
te
d 
23
 N
ov
 2
01
1
15 
 
T253L mutations) did not respond to imatinib dose escalation, as expected, and progressed, 
whereas 7 out of 9 patients harboring F311L and/or M351T mutations responded to dose 
escalation, achieving complete hematological and cytogenetic responses. Overall, 31 CML 
patients remained resistant to imatinib even after dose escalation. 
Currently, screening for BCR-ABL mutations is not recommended in newly diagnosed CP-CML 
patients 25 because the frequency of mutations in these patients was found to be low in previous 
studies, these mutations may not necessarily correlate with response, and the screening costs are 
prohibitive 18, 25, 36, 39. According to the European LeukemiaNet guidelines for CML 
management, mutation analysis of CP-CML patients treated with imatinib should be performed 
when there is evidence of inadequate response or loss of response 25. Our study revealed that 
using sensitive techniques, BCR-ABL KD mutations may be found in a substantial number of 
patients and correlate with the response to imatinib therapy. After the recent approval of two 
second-line TKIs—dasatinib and nilotinib—by the FDA for the frontline treatment of CML, 
knowledge about the presence and type of mutations may facilitate timely decision making 
regarding the choice of therapy at the time of diagnosis. Patients with mutations known to confer 
resistance to standard or high doses of imatinib can benefit from an upfront treatment with a 
second-line TKI. For patients with mutations such as T315I, which is known to confer resistance 
to all currently approved TKIs, one of the newer agents such as ponatinib (AP24534) which is 
effective against this mutation 40-41, or allogeneic transplantation must be considered.  
We acknowledge the fact that there is high incidence of imatinib resistance in our study patients. 
Patients with CML vary in their response to treatment and although the basis for this variation is 
not known, it has been attributed to the biologic heterogeneity of the disease. Some of the factors 
implicated in poor response to CML therapy include low level of expression of molecular 
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transporter hOCT1 and multidrug resistance gene (MDR1) polymorphisms 42,43. Population 
based studies have shown lower efficacy of imatinib in CML patients when compared to the 
clinical trial results. Lucas et el reported 49% imatinib failure by 24 months and suggested 
caution in extrapolating clinical trial data to the general CML population 44. Possible causes of 
inferior results in the community setting include less strict conditions than in the clinical trials, 
lesser motivation and poorer compliance with the treatment. Marin et al recently showed that 
lack of adherence to treatment was an important factor leading to poor results in CML patients 45. 
Poor compliance, inclusion of patients in the late chronic phase and genetic variability are the 
possible explanations for high resistance in our study.  
In summary, we found that by using sensitive techniques like ASO-PCR in CD34+ cells, 
BCR-ABL KD mutations could be detected in almost one-third of CP-CML patients at the time 
of diagnosis and were found to be associated with the outcome of imatinib therapy. Therefore, 
testing for BCR-ABL mutations in CD34+ CML stem/progenitor cells may be cost-effective and 
should be considered before the start of TKI therapy, particularly in patients who present in the 
late CP. Larger population-based studies with longer follow-up times are needed to estimate the 
true incidence of KD mutations in this group of patients and determine whether screening is 
useful in management planning. 
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Table 1. Patient characteristics 
 
Patient characteristics Number (n=100) 
Age (years)      Median 
                         Range 
35 
12-70 
Gender             Male 
                         Female 
69  
31  
Splenic enlargement  
 
87  
Hemoglobin < 10.0 g/dl 
 
55  
WBC count (mm3)   50-100 
                                  >100 
15  
72 
Platelet count          100-450 
                                 >450 
72  
19  
Mode of diagnosis 
           Philadelphia chromosome positive (Ph+) 
           BCR-ABL fusion oncogene positive (BCR/ABL+) 
 
99 
100 
BCR-ABL splice variants 
                                     b2a2 
                                     b3a2 
 
37  
63 
Follow-up (months)    Median     
                                     Range 
30 
8-48 
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Table 2. Sequences of ASO primers and corresponding annealing temperatures (bold 
nucleotides in the primers denote nucleotide changes corresponding to mutations) 
Primer name* Primer 
polarity 
Nucleotide 
change** 
5′-3′ sequence Length
(bases) 
Annealing 
temperature 
1. M244V-F Forward A1094G GAACGCACGGACATCACCG 19 65.7 
2. L248V Forward C1106G ACCATGAAGCACAAGG 16 55 
3. G250E Forward G1113A GAAGCACAAGCTGGGCGA 18 56 
4. Q252H(a) Forward G1120C AGCTGGGCGGGGGCCAC 17 62 
5. Q252H(b) Forward G1120T AGCTGGGCGGGGGCCAT 17 62 
6. Y253H Forward T1121C GCTGGGCGGGGGCCAGC 17 62 
7. Y253F Forward A1122T CTGGGCGGGGGCCAGTT 17 55 
8. E255K Forward G1127A GCGGGGGCCAGTACGGGA 18 68 
9. E255V Forward A1128T GCGGGGGCCAGTACGGGGT 19 58 
244 R Reverse (for 1-9) GCCAATGAAGCCCTCGGAC 19  
10. F311L Forward T932C CACCCGGGAGCCCCCGC 17 62 
 Reverse ( for 10) CCCCTACCTGTGGATGAAGT 20  
11. T315I Forward C1308T GCCCCCGTTCTATATCATCAT 21 63.4 
12. F317L Forward C1315G CCGTTCTATATCATCACTGAGTTG 24 54 
315 R Reverse (for 11-12) GGATGAAGTTTTTCTTCTCCAG 22  
13. M343T Forward T1392C GTGGTGCTGCTGTACAC 17 62 
14. M351T Forward T1416C CCACTCAGATCTCGTCAGCCAC 22 70 
351 R1 Reverse ( for 13-14) GCCCTGAGACCTCCTAGGCT 20  
15. E355G Forward A1428G GTCAGCCATGGAGTACCTAGG 21 56 
16. F359V Forward T1439G GAGTACCTAGAGAAGAAAAACG 22 50 
351 R2 Reverse (for 5-16) ATGCCCAAAGCTGGCTTTG 19  
17. H396R Forward A1551G GGACACCTACACAGCCCG 18 62.5 
369 R Reverse ( for 17) GGACACCTACACAGCCCG 18  
18. F486S Forward T1821C TCTGACCGGCCCTCCTC 17 62 
486 R Reverse (for 18) AGCTTTCTGGTCTCAGGA 18  
 
 
*Substitutions of amino acids; positions according to GenBank no. AAB60394 
for ABL type 1a. 
**Changes of nucleotide; positions according to GenBank no. 
M14752. 
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Table 3. Clinical, cytogenetic, and molecular follow-up studies of CML patients with and 
without BCR-ABL PEMs who received imatinib treatment 
 
 
PEMs: pre-existing mutations; IM: imatinib; CHR: complete hematological response; PHR: 
partial hematological response; CCyR: complete cytogenetic response; MCyR: major 
cytogenetic response; minor CyR: minor cytogenetic response; CMR: complete molecular 
response  
Group Subcategory Number 
of 
patients 
(%) 
Hematological response  
Number (%) 
Cytogenetic response   
Number (%) 
CMR 
Number 
(%) 
CHR PHR No HR CCyR PCyR Minor 
CyR 
Minimal 
CyR 
Group 
1 
Patients 
with PEM 
(A) 
32 (100) 23 
(71.9) 
9 
(28.1) 
------- 17 
(53.1) 
7 (21.9) 3 (9.4) 5 (15.6) -------- 
Group 
2 
 
 
 
 
 
Patients 
without 
PEM 
(B=C+D) 
68 (100) 62 
(91.2) 
3 (4.4) 3 (4.4) 38 
(55.9) 
19 (27.9) 5 (7.4) 6 (8.8) 28 (41.2)
Patients 
without 
PEM 
resistant to 
imatinib (C) 
24 (68) 19 
(79.2) 
2 (8.3) 3(12.5) 7 
(29.2) 
11 (45.8) 2 (8.3) 4 (16.7) ------- 
Patients 
without 
PEM 
susceptible 
to imatinib 
(D) 
44 (68) 43 
(97.7) 
1 (2.3) ------- 31 
(70.5) 
8 (18.2) 3 (6.8) 2 (4.5) 28 (63.6)
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FIGURE LEGENDS 
Figure 1. Detection of BCR-ABL mutations by ASO-PCR and DNA sequencing (-ve control= 
(negative control). HL60 cell line used as a negative control in ASO-PCR and sequencing. 
Figure 2. Comparison of the frequencies of pre-existing BCR-ABL KD mutations and  
mutations detected after manifestation of  imatinib resistance in CML patients.  
Figure 3. Comparison of patients with and without BCR-ABL PEMs in relation to imatinib 
resistance. 
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Figure 1A: Mutation T3151 (1-3: PEM; 4: -ve control; 5: 100bp DNA 
Ladder; 6-8: Mutations after manifestation of IM resistance (IMR))
Figure 1B: Mutation F311L (1: -ve control; 2: 100bp DNA 
Ladder; 3-4: PEM; 5-6: Mutations after manifestation of IMR)
1            2        3        4         5          6 
 1       2        3       4        5         
Figure 1C: Mutation M351T (1: PEM; 2: Mutation after 
manifestation of IMR; 3: -ve control; 5:100bp DNA adder 
   
 
 
112 bp   C944T (T315I)                T311C (F311L)                       T1052C (M351T) 
Figure 1D: Confirmation of PEM by DNA sequencing 
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